Impact of Age on Real-World Outcomes of Bispecific Antibodies in Patients with Relapsed Refractory DLBCL: CUBIC Consortium Analysis
Older patients with diffuse large B-cell lymphoma (DLBCL) have limited treatment options. Bispecific antibodies (BsAbs) are a novel immunotherapy with less acute toxicity compared to conventional therapies. This is a real-world analysis conducted to understand the safety and efficacy of BsAbs in older compared to younger patients. Adult patients with relapsed/refractory DLBCL who received commercially available BsAbs as a single agent between June 2023 and October 2025 across 10 U.S. centers in the CUBIC consortium were included. Key efficacy outcomes included response rates and survival; safety outcomes included cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). The analysis included 256 patients stratified by 3 age groups: <65 (71 patients), 65-74 (81 patients), ≥75 (104 patients). Median prior lines of therapy was 3, 80% were refractory to most recent therapy, and 40% would have been considered pivotal trial ineligible. At median follow-up of 9 months, the 12-month progression-free survival (PFS) was 30% and 12-month overall survival (OS) was 45%. Grade ≥3 CRS occurred in 5% patients; ICANS grade ≥3 occurred in 2% patients. There was no statistically significant difference in outcomes between the 3 age cohorts <65, 65-74, ≥75 with 12-month PFS 21%, 26%, 38%; 12-month OS 35%, 42%, 49%; grade ≥3 CRS 6%, 5%, 4%; and grade ≥3 ICANS 3%, 2%, 1% respectively. On multivariable analysis, ECOG ≥2 and elevated LDH were associated with inferior PFS and OS. Our analysis demonstrates that BsAbs maintain comparable efficacy and safety across all age groups, including patients ≥75 years.
Authors
- Andrew Philip Jallouk (ORCID: https://orcid.org/0000-0003-4335-7942)
- Mehdi Hamadani (ORCID: https://orcid.org/0000-0001-5372-510X)
- Geoffrey Shouse (ORCID: https://orcid.org/0000-0002-7917-5713)
- Yazeed Sawalha (ORCID: https://orcid.org/0000-0001-6355-3671)
- Gulrayz Ahmed (ORCID: https://orcid.org/0000-0001-6873-9571)
- Alex Francisco Herrera (ORCID: https://orcid.org/0000-0002-9665-7415)
- Shakthi Bhaskar (ORCID: https://orcid.org/0000-0003-4528-6367)
- Sairah Ahmed (ORCID: https://orcid.org/0000-0001-7302-8299)
- Allison Marie Bock (ORCID: https://orcid.org/0000-0002-3174-8877)
- Pallawi Torka (ORCID: https://orcid.org/0000-0002-1681-5883)
- Amy A. Ayers (ORCID: https://orcid.org/0000-0003-4807-2356)
- Reid W. Merryman (ORCID: https://orcid.org/0000-0002-6360-3234)
- Ajay Major (ORCID: https://orcid.org/0000-0001-7261-1335)
- Lü Chen (ORCID: https://orcid.org/0000-0002-4571-7975)
- Christopher R. Flowers (ORCID: https://orcid.org/0000-0002-9524-3990)
- Ayushi Chauhan (ORCID: https://orcid.org/0000-0003-4962-3965)
- Narendranath Epperla (ORCID: https://orcid.org/0000-0002-8216-3457)
- Jennifer Leigh Crombie (ORCID: https://orcid.org/0000-0003-3445-5129)
- Matthew Alexander Lunning (ORCID: https://orcid.org/0000-0002-2761-7612)
- Lorenzo Falchi (ORCID: https://orcid.org/0000-0003-1531-3838)
- Swetha Kambhampati Thiruvengadam
- Jomel Meeko Manzano (ORCID: https://orcid.org/0000-0002-3058-7610)
- Alexey V Danilov
Institutions
- City Of Hope National Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Medical College of Wisconsin (US)
- Huntsman Cancer Institute (US)
- City of Hope (US)
- Dana-Farber Cancer Institute (US)
- Fred and Pamela Buffett Cancer Center (US)
- University of Colorado Anschutz Medical Campus (US)
- The Ohio State University (US)
- University of Nebraska Medical Center (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Blood Advances
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1182/bloodadvances.2026021461
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00